3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
NSCLC
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Everolimus
17
lutetium Lu 177 dotatate
7
Octreotide
7
pasireotide
6
lanreotide
6
gallium Ga 68 dotatate
5
Temozolomide
5
Sunitinib
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
pembrolizumab
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroendocrine Tumors
×
Liquid Biopsy
×
Clear all
NCT05255133
2025-01-06
Liquid-NET
Universiteit Antwerpen
Phase NA
Completed
22 enrolled